Informed patient decision making and consent before medical treatment is a medicolegal requirement that may be beneficial to patients and physicians. Certain medications such as cyclosporine (Neoral®) have important potential risks that patients need to understand before they begin treatment.
Objective:
Documentation of an informed decision-making and consent process for use of the drug cyclosporine in dermatology patients is promoted and encouraged.
Methods:
A sample information sheet and consent form to be used by patients and physicians before and during use of the drug cyclosporine are provided.
Get full access to this article
View all access options for this article.
References
1.
SingerMIShearNH. Informed consent and prescription medications: A Canadian dermatologic perspective. J Cutan Med Surg1996; 1:10–16.
2.
QuaidKAFadenRR. Informed consent for a prescription drug: Impact of disclosed information on patient understanding and medical outcomes. Patient Ed Counsel1990; 15:249–259.
3.
HollabaughESWagnerRF. Patient personal injury litigation against Dermatology Residency Programs in the United States, 1964–1988. Arch Dermatol1990; 126:618–622.
4.
Reibl v. Hughes. 1980: In: Vol. 2 SCR 880.
5.
WalshCB. This prescription may be hazardous to your health: Who is accountable to the patient?J Clin Psychopharmacol1993; 13:68–70.
6.
WolvertonSEKappMB. Informed consent for systemic drugs used in dermatology. In: WolvertonSEWilkinJK, eds. Systemic drugs for skin diseases. Philadelphia: WB Saunders, 1991:400–409.
7.
LambGCGreenS. Can physicians warn patients of potential side effects without fear of causing those side effects?Arch Intern Med1994; 154:2753–2756.
8.
HoVCLuiHMcLeanDI. Cyclosporine in nonpsoriatic dermatoses. J Am Acad Dermatol1990; 23:1248–1259.
9.
ZachariaeH. Long-term use of cyclosporine in dermatology. Arch Dermatol1996; 132:692–694.
10.
MitchellAABennekomCM. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N Engl J Med1995;333:101–106.
11.
Unclassified therapeutic agents: Cyclosporine. In: AHFS Drug Information, Bethesda, MD: American Society of Hospital Pharmacists, 1994:2443–2449.
12.
Cyclosporine: Systemic. In: Advice for the patient: Drug information in lay language. Vol. 2. 14th Ed.Bethesda, MD: The United States Pharmacopeial Convention, 1994:481–483.
GuptaAKBrownMDEllisCN. Cyclosporine in dermatology. J Am Acad Dermatol1989; 21:1245–1255.
15.
HoVSibbaldRG. Sandimmune in the treatment of psoriasis. In: MedScope Inc, ed. Canadian consensus on treatment guidelines. St. Laurent, Quebec: Sandoz Canada Inc., 1992:1–12.
